Voyager Therapeutics (VYGR) Other Accumulated Expenses (2014 - 2026)

Voyager Therapeutics has disclosed Other Accumulated Expenses across 13 years of filings, most recently posting $511000.0 for Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $511000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $511000.0 (changed N/A YoY), and the FY2025 annual result was $549000.0, down 54.29% from the prior year.
• Other Accumulated Expenses came in at $511000.0 for Q1 2026 at Voyager Therapeutics, down from $549000.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $7.0 million in Q3 2024 to a low of $511000.0 in Q1 2026.
• The 5-year median for Other Accumulated Expenses is $3.0 million (2023), against an average of $3.4 million.
• Peak annual rise in Other Accumulated Expenses reached 124.69% in 2024, while the deepest fall reached 62.47% in 2024.
• Voyager Therapeutics' Other Accumulated Expenses stood at $2.8 million in 2022, then climbed by 12.99% to $3.2 million in 2023, then slumped by 62.47% to $1.2 million in 2024, then sank by 54.29% to $549000.0 in 2025, then slipped by 6.92% to $511000.0 in 2026.
• The last three Other Accumulated Expenses figures came in at $511000.0 (Q1 2026), $549000.0 (Q4 2025), and $1.2 million (Q4 2024), per Business Quant data.